Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare but potentially life-threatening condition in which a mother’s immune system mistakenly attacks her baby’s platelets. This immune response can cause dangerously low platelet counts in the fetus, raising the risk of internal bleeding, particularly in the brain.
When doctors detect severe cases before birth, one potential treatment option is an intrauterine platelet transfusion (IUPT). While the procedure can be life-saving, it is also considered high risk for both the baby and the mother.
What the procedure involves
Intrauterine platelet transfusions are performed when a fetus is found to have critically low platelet counts. Since FNAIT can affect multiple pregnancies, this is often detected when the mother previously had a child with the condition.
During the procedure, a doctor uses an ultrasound to guide a thin needle into the umbilical vein. Platelets, either from the mother or from a donor, are then infused directly into the baby’s circulation.
Learn more about FNAIT treatment and care
In some cases, transfusions may need to be repeated weekly until delivery, depending on how quickly platelet levels drop.
Risk to the fetus
Despite being a direct way to raise fetal platelet counts, IUPT does carry risks. Any time a needle enters the womb, there is a chance of bleeding or infection. The needle itself can cause trauma to the umbilical cord or fetal vessels, which may lead to serious complications, including fetal death.
What’s more, the underlying condition can make any trauma even more risky. Because the baby’s platelets are already low, the fetus may not clot efficiently, so even a small injury during the procedure can result in severe bleeding.
However, keep in mind that these risks are generally low, as this is a delicate procedure performed by a specialized team.
Risk to the mother
Although rare, complications for the mother can include infection or bleeding at the insertion site.
Another concern is that the transfusion itself could heighten the mother’s immune response, producing even more antibodies that cross the placenta and worsen the condition.
Weighing risks and benefits
Given the risks involved, intrauterine platelet transfusions are generally reserved for the most severe cases of FNAIT.
In recent years, many specialists have shifted toward less invasive treatments, such as giving the mother intravenous immunoglobulin (IVIG) during pregnancy, sometimes combined with corticosteroids. These therapies can reduce antibody activity and may prevent the need for transfusion.
Still, IUPT remains an important option when fetal bleeding is suspected or when platelet counts are thought to be critically low. When faced with the devastating possibility of intracranial hemorrhage, the potential benefit typically outweighs the risk.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
